EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY-NC 4.0

Camrelizumab plus carboplatin and pemetrexed as first-line therapy for advanced non-squamous non-small-cell lung cancer: 5-year outcomes of the CameL randomized phase 3 study

Caicun Zhou iD, Gongyan Chen, Yunchao Huang, Jianying Zhou, LiZhu Lin, Jifeng Feng, Zhehai Wang, Yongqian Shu iD, Jianhua Shi, Yi Hu, QiMing Wang, Ying Cheng iD und 44 weitere

Journal for ImmunoTherapy of Cancer · 2024-11 · 12 (11) · e009240

DOI: 10.1136/jitc-2024-009240 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 27.11.2024. Verfasst von Caicun Zhou und 55 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China caicunzhou_dr@163.com. Hauptthemen laut MEDLINE: Pemetrexed, Carboplatin, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Jiangsu Hengrui Pharmaceuticals Co., Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

CameL phase 3 study demonstrated the superiority of camrelizumab plus chemotherapy over chemotherapy alone for progression-free survival in patients with previously untreated advanced non-squamous non-small-cell lung cancer (NSCLC) without EGFR / ALK alterations. Here, we present the 5-year outcomes.

Methods

Patients were randomized (1:1) and received 4–6 cycles of camrelizumab plus carboplatin and pemetrexed (n=205) or carboplatin and pemetrexed (n=207) every 3 weeks, followed by maintenance camrelizumab plus pemetrexed or pemetrexed only. Crossover from chemotherapy group to camrelizumab monotherapy was permitted after disease progression.

Results

Median time from randomization to data cut-off was 65.2 months (range, 59.7–72.2). HR for overall survival (OS) was 0.74 (95% CI 0.58 to 0.93; one-sided p=0.0043), and was 0.62 (95% CI 0.49 to 0.79; one-sided p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PemetrexedCarboplatinCarcinoma, Non-Small-Cell LungLung NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsAntibodies, Monoclonal, HumanizedHumansFemaleMaleMiddle AgedAgedAdultAged, 80 and overTreatment Outcome

Stichwörter der Autor:innen

ImmunotherapyLung Cancer

Substanzen

PemetrexedCarboplatincamrelizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China caicunzhou_dr@163.com.
  • Department of Respiratory Medicine, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China.
  • Department of Thoracic Surgery Oncology, Yunnan Cancer Hospital and The Third Affiliated Hospital of Kunming Medical University and Yunnan Cancer Center, Kunming, Yunnan, China.
  • Respiratory Medicine, The First Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, China.
  • Oncology Center, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.
  • Department of Thoracic Medical Oncology, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.

ORCID-Profile: Caicun Zhou, Yongqian Shu, Ying Cheng, Jian Fang, Sheng Hu, Anwen Liu, Hongmei Zhang

Förderung

  • Jiangsu Hengrui Pharmaceuticals Co., Ltd

Zitieren

APA

Zhou, C., Chen, G., Huang, Y., Zhou, J., Lin, L., Feng, J., Wang, Z., Shu, Y., Shi, J., Hu, Y., Wang, Q., Cheng, Y., Wu, F., Chen, J., Lin, X., Wang, Y., Huang, J., Cui, J., Cao, L., …, & Shi, W. (2024). Camrelizumab plus carboplatin and pemetrexed as first-line therapy for advanced non-squamous non-small-cell lung cancer: 5-year outcomes of the CameL randomized phase 3 study. Journal for ImmunoTherapy of Cancer, 12(11), e009240. https://doi.org/10.1136/jitc-2024-009240

Vancouver

Zhou C, Chen G, Huang Y, Zhou J, Lin L, Feng J, et al. Camrelizumab plus carboplatin and pemetrexed as first-line therapy for advanced non-squamous non-small-cell lung cancer: 5-year outcomes of the CameL randomized phase 3 study. Journal for ImmunoTherapy of Cancer. 2024;12(11):e009240. doi:10.1136/jitc-2024-009240

BibTeX
@article{Zhou2024,
  author = {Zhou, Caicun and Chen, Gongyan and Huang, Yunchao and Zhou, Jianying and Lin, LiZhu and Feng, Jifeng and Wang, Zhehai and Shu, Yongqian and Shi, Jianhua and Hu, Yi and Wang, QiMing and Cheng, Ying and Wu, Fengying and Chen, Jianhua and Lin, Xiaoyan and Wang, Yongsheng and Huang, Jianan and Cui, Jiuwei and Cao, Lejie and Liu, Yunpeng and Zhang, Yiping and Pan, Yueyin and Zhao, Jun and Wang, LiPing and Chang, Jianhua and Chen, Qun and Ren, Xiubao and Zhang, Wei and Fan, Yun and He, Zhiyong and Fang, Jian and Gu, Kangsheng and Dong, XiaoRong and Jin, Faguang and Gao, Hongjun and An, Guangyu and Ding, Cuimin and Jiang, Xiaodong and Xiong, Jianping and Zhou, Xiangdong and Hu, Sheng and Lu, Ping and Liu, Anwen and Guo, Shuliang and Huang, Jianjin and Zhu, Chengchu and Zhao, Jian and Gao, Beili and Chen, Yinglan and Hu, Chengping and Zhang, Jian and Zhang, Hongmei and Zhao, Hui and Wang, Zhigao and Ma, Xinjing and Shi, Wei},
  title = {Camrelizumab plus carboplatin and pemetrexed as first-line therapy for advanced non-squamous non-small-cell lung cancer: 5-year outcomes of the CameL randomized phase 3 study},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2024},
  volume = {12},
  number = {11},
  pages = {e009240},
  doi = {10.1136/jitc-2024-009240}
}
Kostenlos starten →